FDA Advisory Committee Unanimously Confirms Efficacy and Clinical Benefit of Leqembi for Early Alzheimer's Disease

Recognizing AIM’s June Advocate of the Month: Mike Razzi

Alzheimer’s Association Statement on CMS Announcement of Registry for Access to FDA-Approved Alzheimer’s Treatments